Immunolabeling for Neurodegenerative Diseases, New Webinar Hosted by Xtalks
/EINPresswire.com/ -- TORONTO, ON--(Marketwired - October 16, 2015) - The live broadcast takes place on Wednesday, October 28, 2015 at 11am EDT (3pm GMT), featuring speakers:
- Li-Huei Tsai, Ph. D., Picower Professor of Neuroscience, The Picower Institute for Learning and Memory, Broad Institute, Senior Associate Member, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology
- Raphael Rozenfeld, Ph.D., Development Scientist, Cell Signaling Technology
Deciphering the Molecular Pathology of Alzheimer's Disease
Alzheimer's disease presents stereotypical pathological features including the abundance of amyloid deposition and tauopathy. Affected brain regions also exhibit reactive astrogliosis, neuroinflammatory responses, and vascular pathology. Neuronal and synaptic loss is also evident. Various mouse lines have been created to investigate Alzheimer's disease and most of the models exhibit a subset of the defining pathological features of the disease. In this webinar the speaker will discuss the use of Alzheimer's disease transgenic mouse models to evaluate pathological features by both traditional immunohistochemistry and new tissue processing methods that enable whole- brain imaging. These immunolabeling methods further the investigation of molecular and neural circuit mechanisms of Alzheimer's disease.
The Use of Highly Validated Antibodies to Study Neurodegenerative Disease
Cell Signaling Technology's (CST) mission to produce high quality and rigorously validated antibodies extends to our neuroscience products. CST uses a comprehensive approach, from the selection of targets that are the most relevant to the scientists' current and future research, to the establishment of models for careful validation of the antibodies, and the formulation of ready-to-use antibodies for various experimental procedures relevant to the targets. The neuroscience portfolio comprises antibodies to cell type, sub-cellular compartment, and cell state markers; antibodies against important neurotransmitters; and a growing product line in the field of neurodegenerative diseases, such as Alzheimer's Disease, Parkinson's, Huntington's, and ALS. Our cutting- edge antibody development technologies allow us to generate highly sensitive and specific antibodies to various amyloid-beta peptides, Tau phosphorylation sites, and other disease-research relevant proteins.
To learn more about this event visit: Immunolabeling for Neurodegenerative Diseases
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
Image Available: http://www.marketwire.com/library/MwGo/2015/10/15/11G067784/Images/CST_logo_200-1303930373821.jpg
Contact:
Dian Razak
Tel: +1 (416) 977-6555 ext 352
Email: drazak@xtalks.com
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
